Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 10Psoriasis 6Leukemia 5Lymphoma, Follicular 4Myelodysplastic Syndromes 3Inflammation 3Asthma 3Arthritis, Juvenile 3Vasculitis 2Uveitis 2Respiratory Distress Syndrome 2Recurrence 2Prostatic Neoplasms 2Pneumonia 2Neuroblastoma 2Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Wilms Tumor 1Temporomandibular Joint Disorders 1Stomatitis 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1

Interventions

Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lupus Nephritis × Etanercept × Clear all
NCT00447265 2013-02-12

Etanercept for the Treatment of Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Terminated
1 enrolled 15 charts

Lupus Nephritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡